Metraipolis › archive › dc_93cf03b765d2
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial — Europe PMC PMID:41237344
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41237344
- DOI
- 10.1182/blood.2025031006
- License (as archived)
- solo-consultazione
- Archived
- 2026-10-08T06:02:51.128Z
- SHA-256 of the archived text
cc51da4448dbbae0631ba1fb342a6e1a71c144929326886cb3214580b3e45656- Stable URL of this page
https://metraipolis.com/documento/dc_93cf03b765d2
How to cite
CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial — Europe PMC PMID:41237344 — Europe PMC (en), https://europepmc.org/article/MED/41237344 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_93cf03b765d2 (Metraipolis archive dc_93cf03b765d2, sha256 cc51da4448dbbae0631ba1fb342a6e1a71c144929326886cb3214580b3e45656)
BibTeX
@misc{dc93cf03b765d2,
title = {CPX-351 vs daunorubicin, cytarabine, and gemtuzumab ozogamicin in older adults with non-adverse-risk AML: the NCRI AML18 trial — Europe PMC PMID:41237344},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41237344},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_93cf03b765d2; sha256 cc51da4448dbbae0631ba1fb342a6e1a71c144929326886cb3214580b3e45656},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41237344. Agents can read the archived copy with the MCP tool read_document.